BR9508991A - Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvel - Google Patents
Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvelInfo
- Publication number
- BR9508991A BR9508991A BR9508991A BR9508991A BR9508991A BR 9508991 A BR9508991 A BR 9508991A BR 9508991 A BR9508991 A BR 9508991A BR 9508991 A BR9508991 A BR 9508991A BR 9508991 A BR9508991 A BR 9508991A
- Authority
- BR
- Brazil
- Prior art keywords
- increasing
- treatment
- compound
- human
- gastrointestinal
- Prior art date
Links
- 238000000034 method Methods 0.000 title 3
- 150000001875 compounds Chemical class 0.000 title 2
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 208000025865 Ulcer Diseases 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 201000001421 hyperglycemia Diseases 0.000 title 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 title 1
- 201000008980 hyperinsulinism Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 230000036269 ulceration Effects 0.000 title 1
- 230000004584 weight gain Effects 0.000 title 1
- 235000019786 weight gain Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/303—Cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3223—Esters of cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9415304A GB9415304D0 (en) | 1994-07-29 | 1994-07-29 | Novel compounds |
| GB9423179A GB9423179D0 (en) | 1994-11-17 | 1994-11-17 | Novel compounds |
| GBGB9510485.7A GB9510485D0 (en) | 1995-05-24 | 1995-05-24 | Novel compounds |
| PCT/EP1995/003037 WO1996004233A1 (en) | 1994-07-29 | 1995-07-27 | Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9508991A true BR9508991A (pt) | 1997-10-21 |
Family
ID=27267307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9508991A BR9508991A (pt) | 1994-07-29 | 1995-07-27 | Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvel |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0772585A1 (cs) |
| JP (1) | JPH10503507A (cs) |
| CN (1) | CN1159797A (cs) |
| AU (1) | AU3254695A (cs) |
| BR (1) | BR9508991A (cs) |
| CA (1) | CA2196193A1 (cs) |
| CZ (1) | CZ25597A3 (cs) |
| HU (1) | HUT76800A (cs) |
| MX (1) | MX9700765A (cs) |
| NO (1) | NO970372L (cs) |
| PL (1) | PL318381A1 (cs) |
| WO (1) | WO1996004233A1 (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9605495D0 (en) * | 1996-03-15 | 1996-05-15 | Smithkline Beecham Plc | Novel compounds |
| US5914339A (en) * | 1996-05-14 | 1999-06-22 | American Home Products Corporation | Substituted 1,3-benzodioxoles |
| EP0827746B1 (en) | 1996-09-05 | 2002-04-03 | Eli Lilly And Company | Carbazole analogues as selective beta3 adrenergic agonists |
| WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
| GB9703492D0 (en) * | 1997-02-20 | 1997-04-09 | Smithkline Beecham Plc | Novel compounds |
| CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| DK0980375T3 (da) * | 1998-01-30 | 2006-03-13 | Boulder Scient Co | Syntese af silylerede og N-silylerede forbindelser |
| DE69940484D1 (de) | 1998-04-06 | 2009-04-09 | Astellas Pharma Inc | Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie |
| AUPP549998A0 (en) * | 1998-08-26 | 1998-09-17 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| US7098248B2 (en) * | 2001-07-09 | 2006-08-29 | Research Development Foundation | Beta-adrenergic blockade reversal of catabolism after severe burn |
| DE102008064003A1 (de) * | 2008-12-19 | 2010-06-24 | Clariant International Limited | Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung |
| CN107266341B (zh) * | 2017-06-23 | 2020-01-07 | 华东师范大学 | 芳氧基取代丙-2-醇胺的衍生物作为β3肾上腺素能受体拮抗剂、制备方法和用途 |
| CN112442167A (zh) * | 2019-08-28 | 2021-03-05 | 广东广山新材料股份有限公司 | 一种反应型阻燃剂及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1262729A (en) * | 1983-10-19 | 1989-11-07 | Leo Alig | Phenoxypropanolamines |
| DE3866984D1 (en) * | 1987-07-21 | 1992-01-30 | Hoffmann La Roche | Phenoxypropanolamine. |
| GB8801306D0 (en) * | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
| GB9215844D0 (en) * | 1992-07-25 | 1992-09-09 | Smithkline Beecham Plc | Novel compounds |
-
1995
- 1995-07-27 WO PCT/EP1995/003037 patent/WO1996004233A1/en not_active Ceased
- 1995-07-27 MX MX9700765A patent/MX9700765A/es unknown
- 1995-07-27 CZ CZ97255A patent/CZ25597A3/cs unknown
- 1995-07-27 CN CN95195371A patent/CN1159797A/zh active Pending
- 1995-07-27 PL PL95318381A patent/PL318381A1/xx unknown
- 1995-07-27 BR BR9508991A patent/BR9508991A/pt not_active Application Discontinuation
- 1995-07-27 AU AU32546/95A patent/AU3254695A/en not_active Abandoned
- 1995-07-27 JP JP8506193A patent/JPH10503507A/ja active Pending
- 1995-07-27 HU HU9700262A patent/HUT76800A/hu unknown
- 1995-07-27 CA CA002196193A patent/CA2196193A1/en not_active Abandoned
- 1995-07-27 EP EP95929029A patent/EP0772585A1/en not_active Withdrawn
-
1997
- 1997-01-28 NO NO970372A patent/NO970372L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0772585A1 (en) | 1997-05-14 |
| AU3254695A (en) | 1996-03-04 |
| WO1996004233A1 (en) | 1996-02-15 |
| CZ25597A3 (cs) | 1998-02-18 |
| NO970372L (no) | 1997-03-18 |
| MX9700765A (es) | 1997-05-31 |
| NO970372D0 (no) | 1997-01-28 |
| PL318381A1 (en) | 1997-06-09 |
| HUT76800A (en) | 1997-11-28 |
| CN1159797A (zh) | 1997-09-17 |
| JPH10503507A (ja) | 1998-03-31 |
| CA2196193A1 (en) | 1996-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9508991A (pt) | Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvel | |
| BR0306982A (pt) | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto | |
| WO2003060475A3 (en) | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues | |
| Tembe-Fokunang et al. | The potential pharmacological and medicinal properties of neem (Azadirachta indica A. Juss) in the drug development of phytomedicine | |
| CN108135963A (zh) | 用于促进葡萄糖转运的肽 | |
| WO2003059289A3 (en) | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | |
| BR112015020019B1 (pt) | forma de dosagem farmacêutica e seu uso | |
| Krook et al. | Nutritional secondary hyperparathyroidism in the animal kingdom: report of two cases | |
| EA027651B1 (ru) | Биологически активная добавка к пище для нормализации функции щитовидной железы | |
| Biolcati et al. | Creeping eruption of larva migrans-A case report in a beach volley athlete | |
| Wendo | Uganda revises cattle treatment to protect humans from sleeping sickness. | |
| Nurmi et al. | The impact of clamp castration on the behaviour and body temperature of reindeer (Rangifer tarandus tarandus)–Effects of local anesthesia and non-steroidal anti-inflammatory drug. | |
| Cronin | Nutraceutical of the next century? | |
| RU94042745A (ru) | Способ профилактики, нормализации и лечения нарушений и болезней обмена веществ у молодняка крупного рогатого скота | |
| Mandal et al. | A study to evaluate efficacy of Tinospora cordifolia (Guduchi) as analgesic agent using albino wistar rats as an experimental animal model | |
| Calhoun et al. | Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat | |
| Karkola et al. | Deaths caused by animals in Finland | |
| BR0311574A (pt) | Uso de uma composição à base de ketoprofeno para a produção de uma alimentar suplementada | |
| Emeash et al. | Stress resulting of management practices on sheep herds | |
| WO2025023085A1 (ja) | 歯周病予防・治療剤 | |
| Solanki et al. | Indigenous knowledge of veterinary medicines among tribals of West Nimar. | |
| Henderson et al. | Maxillary dento-alveolar abscess in a spotted hyaena Crocuta crocuta | |
| US20210369735A1 (en) | Phytoecdysones for use in the prevention of muscle strength loss during immobilisation | |
| RU2634347C1 (ru) | Лечебно-профилактическая зубная паста | |
| RU2000125984A (ru) | Способ лечения и профилактики железодефицитной анемии у сельскохозяйственных животных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| FA8 | Dismissal: dismissal - article 36, par. 1 of industrial property law |